Henry E. Pelish, Chief Scientific Officer at Nuvalent, Inc. (NUVL), sold 14,850 shares at $79.94 ($1.2M) on 2025-07-10, disclosed to the SEC on 2025-07-11.
Scheduled sale ($1.2M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $81.08 | 1,945 | $158K | 13.2% |
| 2 | $81.08 | 1,945 | $158K | 13.2% |
| 3 | $81.90 | 200 | $16K | 1.4% |
| 4 | $79.94 | 5,260 | $420K | 35.3% |
| 5 | $79.94 | 5,260 | $420K | 35.3% |
| 6 | $80.92 | 240 |
| $19K |
| 1.6% |
| Total | $80.28 avg | 14,850 | $1.2M | 100% |
| Filing → |
| NUVL | SELL | 2026-03-16 | $3.4M | — | Filing → |
| NUVL | SELL | 2026-01-07 | $502K | — | Filing → |
| NUVL | SELL | 2025-10-17 | $2.6M | — | Filing → |